Skip to main content
SpringerLink
Log in

Antiangiogenese-Ansätze in der Tumortherapie

Anti-angiogenic approaches in tumor therapy

  • Themenschwerpunkt: Chirurgische Onkologie An Der Jahrtausendwende
  • Published:
Acta Chirurgica Austriaca Aims and scope Submit manuscript

Zusammenfassung

Grundlagen: Tumorwachstum und Metastasierung erfordern eine ausreichende Versorgung durch Blutgefäße, die weitgehend neu gebildet werden müssen. Der Prozeß der Angiogenese bietet daher einen vielversprechenden Angriffspunkt in der Tumortherapie.

Methodik: Der Artikel stellt eine Zusammenfassung der wesentlichsten Erkenntnisse auf dem Gebiet der Tumorangiogenese dar und gibt einen Überblick über die vielfachen Anwendungen im Bereich der Tumordiagnose und Tumortherapie.

Ergebnisse: Klinische Studien der Phase I und II mit Angiogeneseinhibitoren an soliden Tumoren haben erste, positive Resultate ergeben: Stabilisierung der Erkrankung bzw. partielle Response wurden vielfach für Nierenzellkarzinome und Kaposi-Sarkome berichtet. Die Nebenwirkungen wurden (mit wenigen Ausnahmen) als mäßig eingestuft. Es zeigten sich keine Resistenzerscheinungen.

Schlußfolgerungen: Antiangiogenese-Ansätze und deren Kombination mit konventionellen Therapieformen gewinnen zunehmend an Bedeutung und stellen eine vielversprechende, neue Richtung der Tumorbehandlung dar.

Summary

Background: Tumor growth and metastasis require adequate blood supply via the generation of new vessels. Angiogenesis therefore seems to be an attractive target in tumor therapy.

Methods: The article summarizes the essential mechanisms of tumor angiogenesis and gives an overview on the various applications in cancer diagnosis and treatment.

Results: Phase I and II clinical trials with various inhibitors of angiogenesis gave promising results, i. e. stable disease or partial response was reported for renal cell carcinoma and Kaposi’s sarcoma patients. With a few exceptions, treatments were well tolerated and did not lead to drug resistance.

Conclusions: Inhibition of angiogenesis and possible combinations with conventional forms of cancer treatment represent a new and promising area of tumor therapy, which will certainly gain further importance in the years to come.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Literatur

  1. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ: A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989–1995.

    PubMed  CAS  Google Scholar 

  2. Boehm T, Folkman J, Browder T, MS OR: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404–407.

    Article  PubMed  CAS  Google Scholar 

  3. Carter SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000;5(Suppl 1):51–54.

    Article  PubMed  CAS  Google Scholar 

  4. D’Amore PA, Shima DT: Tumor angiogenesis: a physiological process or genetically determined? Cancer Metastasis Rev 1996;15:205–212.

    Article  PubMed  CAS  Google Scholar 

  5. Dezube BJ, Von Roenn JH, Holden Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS: Fumagillin analog in the treatment of Kaposi’s sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444–1449.

    PubMed  CAS  Google Scholar 

  6. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME: Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82:812–817.

    Article  PubMed  CAS  Google Scholar 

  7. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.

    PubMed  CAS  Google Scholar 

  8. Fox SB, Harris AL: Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. Invest New Drugs 1997;15:15–28.

    Article  PubMed  CAS  Google Scholar 

  9. Friedl J, Gnant MX, Bartlett D, Libutti S: Rapid induction of permeability across endothelial cell monolayers by tumor necrosis factor occurs via a tissue factor dependent mechanism: relationship between the procoagulant and permeability effects of TNF. Cancer Res 2000;submitted.

  10. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998.

    Article  PubMed  CAS  Google Scholar 

  11. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505–515.

    Article  PubMed  CAS  Google Scholar 

  12. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501–1505.

    PubMed  CAS  Google Scholar 

  13. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135–1149.

    PubMed  CAS  Google Scholar 

  14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999;13:9–22.

    PubMed  CAS  Google Scholar 

  15. Nugent MA, Iozzo RV: Fibroblast growth factor-2. Int J Biochem Cell Biol 2000;32:115–120.

    Article  PubMed  CAS  Google Scholar 

  16. Quinn TE, Thurman GB, Sundell AK, Zhang M, Hellerqvist CG: CM101, a polysaccharide antitumor agent, does not inhibit wound healing in murine models. J Cancer Res Clin Oncol 1995;121:253–256.

    Article  PubMed  CAS  Google Scholar 

  17. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324–1330.

    PubMed  CAS  Google Scholar 

  18. Risau W: Angiogenesis is coming of age. Circ Res 1998;82:926–928.

    PubMed  CAS  Google Scholar 

  19. Risau W: Mechanisms of angiogenesis. Nature 1997;386:671–674.

    Article  PubMed  CAS  Google Scholar 

  20. Sato TN, Tozawa Y, Deutsch U, Wolburg Buchholz K, Fujiwara Y, Gendron Maguire M, Gridley T, Wolburg H, Risau W, Qin Y: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70–74.

    Article  PubMed  CAS  Google Scholar 

  21. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735–745.

    Article  PubMed  CAS  Google Scholar 

  22. Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541–2545.

    PubMed  CAS  Google Scholar 

  23. Steward WP: Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 1999;43(Suppl):56–60.

    Article  Google Scholar 

  24. Thompson WD, Li WW, Maragoudakis M: The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol 2000;190:330–337.

    Article  PubMed  CAS  Google Scholar 

  25. Thorpe PE, Burrows FJ: Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 1995;36:237–251.

    Article  PubMed  CAS  Google Scholar 

  26. Varner JA, Cheresh DA: Tumor angiogenesis and the role of vascular cell integrin avß3. Important Adv Oncol 1996;69–87.

  27. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9–19.

    PubMed  CAS  Google Scholar 

  28. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996;70:6831–6838.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chirurgische Forschungslaboratorien, Universitätsklinik für Chirurgie, Wien, Währinger Gürtel 18–20, A-1090, Wien

    Christine Brostjan, S. Roka, A. Gornikiewicz & J. Friedl

Authors
  1. Christine Brostjan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Roka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Gornikiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Friedl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Brostjan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brostjan, C., Roka, S., Gornikiewicz, A. et al. Antiangiogenese-Ansätze in der Tumortherapie. Acta Chir. Austriaca 32, 251–254 (2000). https://doi.org/10.1007/BF02949148

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02949148

Schlüsselwörter

Keywords

Search

Navigation